Using modified herpes virus to enhance melanoma treatment
Oncolytic Herpes Simplex Virus (HSV)1 as adjuvants for melanoma
This study is exploring a new way to treat melanoma using a specially modified herpes virus that helps your immune system fight cancer better, especially for tumors that haven't responded well to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ Hsc Shreveport NIH-funded |
| Lab location | 1 site (Shreveport, United States) |
| Project ID | NIH-11128479 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve melanoma treatment by using a modified version of the herpes simplex virus (HSV1). The modified virus is designed to trigger a specific type of cell death, known as necroptosis, within the tumor environment, which can enhance the immune response against cancer cells. By increasing the immunogenicity of the tumor microenvironment, the goal is to make previously resistant tumors more responsive to immunotherapy. Patients may benefit from this innovative treatment strategy that aims to overcome the limitations of current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma, particularly those whose tumors are resistant to standard immunotherapy.
Not a fit: Patients with non-melanoma skin cancers or those who have already responded well to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for melanoma patients who currently do not respond to existing therapies.
How similar studies have performed: Previous research has shown promise in using oncolytic viruses for cancer treatment, indicating that this approach may lead to significant advancements in melanoma therapy.
Where this research is happening
Shreveport, United States
- Louisiana State Univ Hsc Shreveport — Shreveport, United States (Active)
Researchers
- Principal investigator: Guo, Hongyan — Louisiana State Univ Hsc Shreveport
- Study coordinator: Guo, Hongyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.